Top News
Rates of Head, Neck Melanoma Up in North American Youth
Differences in Postrelapse Mortality May be Driving Racial/Ethnic Disparities Observed in Children With Hodgkin Lymphoma
Physician Experience With Rituximab Affected Rate of Early Discontinuation in NHL
Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia
Single Nucleotide Polymorphisms Associated With ALL in Children With Down Syndrome
ASCO Releases Guideline on Addressing Osteoporosis Risk With Nonmetastatic Cancer
Two New Radiomics Features Predict Lung Cancer Survival in LDCT Screening
Low-Dose Computed Tomography Used to Screen First Responders for Lung Cancer
Genomic Assay Shows Utility in Selecting NSCLC Patients for Targeted Therapy
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity. -
IASLC North America 2019 Coverage
News coverage from the IASLC North America Conference on Lung Cancer 2019 meeting in Chicago, IL. -
Dietary Acrylamide and Cancer
This fact sheet provides an overview of data on dietary acrylamide and the risk of developing cancer. -
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed. -
Clinical Missteps Obscuring a Lung Cancer Diagnosis
Although the rate of cancer misdiagnosis is quite high across malpractice claims, this number does not necessarily correlate with what occurs in clinical practice, an expert warned. -
Immune Response to Isatuximab Correlates With Clinical Response in Patients with Relapsed or Refractory Multiple Myeloma
Could myeloma-associated antibodies could one day serve as biomarkers for predicting which patients will benefit from isatuximab? -
Digital Biopsies: Radiomics and Pathomics Are Important Stops on the Path to Precision Medicine
Single biomarkers can only go so far in predicting responses given the complexity and heterogeneity of individual malignancies and their microenvironments. -
First-in-Class Antibody-Drug Conjugate Advances to Clinical Trial
An antibody-drug conjugate showed antitumor activity in preclinical models for pancreatic cancer, among other cancer types, leading to a phase 1 clinical trial.
More Features
Measurable Residual Disease: The Future of Multiple Myeloma Assessment?
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
Study of Ibrutinib in CLL Shows a Benefit, but Raises Crucial Questions
The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use.
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap.
Adherence to the World Cancer Research Fund Recommendations and Colorectal Cancer Risk: Examining the Link
Adherence to the 2018 WCRF/AICR recommendations as measured by a multicomponent “lifestyle score” was associated with a statistically significant decreased risk of CRC in men.
